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titis has been debated for more than 40 years [1–4]. Although a
large number of controlled clinical trials have been performed,
there is still insufﬁcient evidence to support glucocorticosteroids
for patients with alcoholic hepatitis [4]. Since autoimmunity is
not a signiﬁcant feature of this disease, the rationale behind the
use of glucocorticosteroids, is to block cytotoxic and inﬂamma-
tory pathways [5]. However, the potential side-effects of gluco-
corticosteroids are numerous including anti-anabolism, muscle
breakdown (proteolysis), immunosuppression, increased suscep-
tibility to infection, and increased risk of GI bleeding.
Originally, glucocorticosteroids were claimed to beneﬁt any
patient with alcoholic hepatitis. Later the beneﬁcial effect was
restricted to those with hepatic encephalopathy, later again, to
those with a Maddrey discriminant functionP32. Most recently,
the group with a claimed beneﬁcial effect of glucocorticosteroids
has been reduced even further. In a study from Glasgow the ben-
eﬁcial effect was conﬁned to the subgroup of patients with a
Maddrey discriminant function P32 and a Glasgow alcoholic
hepatitis score P9 [6]. However, this study was not performed
as a controlled study. In the minority of the patients, who were
included in randomised controlled trials, there was no signiﬁcant
beneﬁcial effect of glucocorticosteroid therapy in the subgroup in
question [6].
Recently the so-called Lille prognostic model has been used to
identify ‘responders’ and ‘non-responders’ to glucocorticosteroid
therapy in alcoholic hepatitis [7]. This model has been developed
and validated exclusively for glucocorticosteroid treated patients
[7]. The predominant variable in the Lille model is the one week
change in bilirubin. A decrease in this variable from day 0 to day
7 is considered a major indicator of being a ‘responder’ to gluco-
corticosteroid therapy. The ‘non-responders’, according to the
Lille model, have a six month survival of only 25% on glucocorti-
costeroid therapy [7].
In a recent meta-analysis based on individual data from the
ﬁve latest randomised controlled trials, the beneﬁcial effect of
glucocorticosteroids was conﬁned to the subgroup of ‘responders’
according to the Lille model [8]. The ‘non-responders’ according
to the model had no signiﬁcant effect from glucocorticosteroid
therapy. The problem with this analysis is that the Lille modelJournal of Hepatology 20
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patients. The control groups in this meta-analysis were not trea-
ted with glucocorticosteroids and the Lille model may not apply
to those patients. Most likely the coefﬁcients in the model would
be different in the control patients. There could even be an inter-
action between the therapy (glucocorticosteroid/control) and the
variables included in the model calling for a comprehensive anal-
ysis based on data from both treatment and control patients [9].
Considering all these reasons, the results of this meta-analysis
seem questionable. Furthermore, the study was based on a
selected part of the available trials [4], possibly suggesting a
selection bias.
The Lille group has recognized that infections may be a seri-
ous problem of glucocorticosteroid therapy in alcoholic hepatitis
[10]. Nevertheless, it has been suggested that all patients with
the disease should have at least one week of glucocorticosteroids
to see if they would be ‘responders’ (decrease in bilirubin from
day 0 to day 7) according to the Lille model. This strategy implies
that potential ‘non-responders’ would need to receive one week
of therapy, which may be deleterious, and possibly lead to a six
month survival probability of only 25% [7]. Such a strategy seems
very problematic.
Over the years the evidence in favour of glucocorticosteroid
therapy in alcoholic hepatitis has steadily decreased, and now it
seems to be the time to move on to other therapies with more
potential, e.g., pentoxifylline.Conﬂicts of interest
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